文献速递分子诊断临床免疫

ddPCR与NGS法检测肾移植后供体来源游离DNA百分比高度一致

High Concordance between ddPCR- and NGS-Based Quantification of Donor-Derived Cell-Free DNA Percentage after Kidney Transplantation.
PubMed 文献 · Clin Chem · 2026-06-11

本研究比较两种供体来源游离DNA检测方法:基于NGS的AlloSeq(202个SNP)和基于ddPCR的GraftAssure(45个SNP),共检测254份样本。结果显示两者高度一致(Pearson r=0.96),在0.5%阈值下符合率达99.2%,支持根据成本和可及性灵活选择检测方法。

要点

  • AlloSeq与GraftAssure检测dd-cfDNA高度一致,Pearson r=0.96。
  • 在0.5%临床相关阈值下,两种方法符合率达99.2%。
  • 稳定患者中dd-cfDNA水平低且一致,支持方法互换使用。

核心结论

  • 两种dd-cfDNA检测方法(NGS与ddPCR)诊断一致性优秀,支持根据可及性和成本灵活选择。

研究设计与样本

  • 比较两种dd-cfDNA检测方法,共254份样本:134份来自97例接受指征活检和重复dd-cfDNA检测的患者,120份来自44例临床稳定患者。

主要发现

  • AlloSeq与GraftAssure的dd-cfDNA值高度一致,Pearson r=0.96。
  • 在0.5%阈值下,两种方法符合率达99.2%。
  • 抗体介导排斥反应中dd-cfDNA水平最高:AlloSeq 1.96±1.06%,GraftAssure 2.08±1.07%,P=0.99。
  • 稳定移植物功能患者中dd-cfDNA水平低且一致:AlloSeq 0.18±0.11%,GraftAssure 0.17±0.13%。
  • 18例稳定患者(每人至少3次高于定量检测限)使用GraftAssure分析生物学变异,个体内变异系数9.7%,中位dd-cfDNA 0.17%时参考变化值40.9%。

关键数值与推荐

  • AlloSeq基于NGS检测202个SNP,GraftAssure基于ddPCR分析45个SNP。
  • 0.5%为临床相关阈值,两种方法符合率99.2%。
  • 稳定患者中位dd-cfDNA 0.17%时,个体内变异系数9.7%,参考变化值40.9%。

临床怎么用

  • 临床可根据可及性和成本在NGS法与ddPCR法之间灵活选择dd-cfDNA检测,支持将其整合进常规移植监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Donor-derived cell-free DNA (dd-cfDNA) enables early detection and monitoring of graft injury after transplantation. However, clinical adoption has been slowed by pricing and limited reimbursement. Commercially available assays based on different methodologies are used in practice, but their comparability remains uncertain. Demonstrating interchangeability may support more cost-effective use in transplant surveillance. METHODS: This study compared 2 dd-cfDNA assays in 254 samples: 134 samples from 97 patients undergoing indication biopsy and repeated dd-cfDNA testing, and 120 samples from 44 clinically stable patients. Both assays quantify dd-cfDNA via predefined single nucleotide polymorphisms (SNPs): AlloSeq (CareDx) detects 202 SNPs using next-generation sequencing, while GraftAssure (Insight Molecular Diagnostics) analyzes 45 SNPs using droplet digital PCR. RESULTS: dd-cfDNA values demonstrated excellent agreement between AlloSeq and GraftAssure (Pearson's r = 0.96). At a clinically relevant threshold of 0.5%, assay concordance reached 99.2%. The highest dd-cfDNA levels were observed in antibody-mediated rejection (mean ± standard deviation: AlloSeq 1.96 ± 1.06%, GraftAssure 2.08 ± 1.07%; P = 0.99). Among patients with stable graft function, dd-cfDNA levels were similarly low and consistent (AlloSeq 0.18 ± 0.11%, GraftAssure 0.17 ± 0.13%). Biological variability analysis using GraftAssure in 18 stable patients, each with at least 3 values above the quantitative detection limit, revealed an intraindividual coefficient of variation of 9.7% and a reference change value of 40.9% at a median dd-cfDNA level of 0.17%. CONCLUSIONS: This study provides the first comparison of 2 established dd-cfDNA testing methods and demonstrates excellent diagnostic agreement. These findings support flexibility in assay selection based on availability and cost, supporting the integration of dd-cfDNA testing into routine practice. GERMAN CLINICAL TRIALS REGISTRY: DRKS00023604.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Reineke M, Loi L, Schröter I, et al. High Concordance between ddPCR- and NGS-Based Quantification of Donor-Derived Cell-Free DNA Percentage after Kidney Transplantation. Clin Chem. 2026. PMID: 42271643. doi:10.1093/clinchem/hvag056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。